SVF
Level A· Stronger Clinical EvidenceSystematic Review

The Potency of Adipose-Derived Mesenchymal Stem Cells to Increase Ovarian Function in Primary Ovarian Insufficiency: A Systematic Review of in vivo Studies.

Adventa YI., Adventa YI., Rachmawati A., Tjahyadi D.

Systematic Review with a reported sample of 5 on Hair & Scalp, published in Gynecol Obstet Invest (2025) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Gynecol Obstet Invest (2025)
Country
Switzerland
Reported sample size
5
PMID
39965550
DOI
10.1159/000544721

Abstract (original English)

Primary ovarian insufficiency (POI) that caused infertility could decrease the quality of life in women. Therefore, an effective treatment is needed. Adipose-derived stem cells (ADSCs) have been reported to have therapeutic benefits in POI. This review aims to evaluate the therapeutic effect of ADSCs in POI. Literature studies were searched according to PRISMA 2020 guidelines in the following databases: PubMed, ProQuest, Wiley, Emerald, and JSTOR (until July 10th, 2024). The study inclusion criteria are original articles, in vivo study with adipose-derived stem cell therapy towards POI with ovarian function as the outcome. SYRCLE's risk of bias tool was used to evaluate the quality of the studies. We retrieved 9 from 292 articles published in English between 2013 and 2024. Animals used in this study were mice (n = 5) and rats (n = 4). ADSCs were administered either systematically or directly by injection into the ovaries. Decreased apoptosis, increased follicle survival, and hormone levels were observed. These showed that ADSCs implantation could improve ovarian function in rats and mice. Overall, ADSCs in POI showed satisfactory results. ADSCs showed benefits in increasing ovarian function in POI. Further studies, especially human studies, are needed to evaluate the efficacy and side effects of the ADSCs treatment before reaching general conclusions.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Primary Ovarian InsufficiencyFemaleAnimalsMesenchymal Stem Cell TransplantationMiceRatsOvaryAdipose TissueHumansMesenchymal Stem Cells
Hair & Scalp
View on PubMedDOI

Related research